Skip to main content
Download PDF

A systematic review and meta-analysis on mortality rate following total pelvic exenteration in cancer patients

BMC Cancer volume 24, Article number: 593 (2024) Cite this article

Abstract

Background

Total pelvic exenteration (TPE), an en bloc resection is an ultraradical operation for malignancies, and refers to the removal of organs inside the pelvis, including female reproductive organs, lower urological organs and involved parts of the digestive system. The aim of this meta-analysis is to estimate the intra-operative mortality, in-hospital mortality, 30- and 90-day mortality rate and overall mortality rate (MR) following TPE in colorectal, gynecological, urological, and miscellaneous cancers.

Methods

This is a systematic review and meta-analysis in which three international databases including Medline through PubMed, Scopus and Web of Science on November 2023 were searched. To screen and select relevant studies, retrieved articles were entered into Endnote software. The required information was extracted from the full text of the retrieved articles by the authors. Effect measures in this study was the intra-operative, in-hospital, and 90-day and overall MR following TPE. All analyzes are performed using Stata software version 16 (Stata Corp, College Station, TX).

Results

In this systematic review, 1751 primary studies retrieved, of which 98 articles (5343 cases) entered into this systematic review. The overall mortality rate was 30.57% in colorectal cancers, 25.5% in gynecological cancers and 12.42% in Miscellaneous. The highest rate of mortality is related to the overall mortality rate of colorectal cancers. The MR in open surgeries was higher than in minimally invasive surgeries, and also in primary advanced cancers, it was higher than in recurrent cancers.

Conclusion

In conclusion, it can be said that performing TPE in a specialized surgical center with careful patient eligibility evaluation is a viable option for advanced malignancies of the pelvic organs.

Peer Review reports

Introduction

Total pelvic exenteration (TPE), an en bloc resection is an ultraradical operation for malignancies which was performed for the first time in 1946 by Alexander Brunschwig [1], and refers to the removal of organs inside the pelvis, including female reproductive organs, lower urological organs and involved parts of the digestive system (rectosigmoid) [2,3,4].

TPE procedure is used in the treatment of advanced gynecological cancers as well as primary advanced and recurrent rectal cancers [3, 5]. Even though TPE is infrequently performed, it may be considered as the last hope for the treatment of recurrent or advanced cancers [6, 7].

TPE technique was associated with significant complications and mortality in the first decades, but in recent decades due to the improvement of preoperative planning (whole-body positron emission tomography), intraoperative and postoperative care, the survival rate, surgical complications and mortality of candidate patients has improved significantly [4, 8, 9].

Overall survival and disease-free survival rate significantly improved following TPE, especially in well-selected patients [3]. To the best of our knowledge, the highest 5 years overall survival rate was reported as 65.8% [10] in cervical cancer patients following pelvic exenteration and in colorectal cancer patients, one year survival rate was more than 80% in several previous studies [11,12,13,14] and the highest five year survival rate was reported as 92.9% in a study by Mark Katory et al. in the United Kingdom [14].

Considering that this surgical technique is considered a rare and advanced technique, significant complications and mortality rate (MR) have been reported for it. Intra-operative mortality, in-hospital mortality, 30- and 90-day mortality are important consequences that are reported for the management of the complications of this surgery. In addition to the survival rate, mortality and complications are also changing over time and depend on the equipment of the surgical center as well as the experience of the surgical team, and different studies have reported different mortality rates and there is no comprehensive review in this regard. The aim of this meta-analysis is to estimate the intra-operative mortality, in-hospital mortality, 30- and 90-day mortality rate and overall mortality rate following TPE in colorectal, gynecological, urological, and miscellaneous.

Methods

Study design

This is a systematic review and meta-analysis in which international databases were searched to find the relevant studies. Standard guideline of “Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was followed to prepared the report. This study was registered in the PROSPERO (CRD42023467479).

Eligibility criteria

In this study, all observational studies related to the MR after TPE surgery with English full-text were included in the study. There was no time limit for entering the articles, and also in terms of the study design, all the articles that reported the MR including cohort studies, cross-sectional studies and case series studies were included. However, studies which had not defined the surgical procedure of TPE routinely were excluded. Additionally, we excluded case reports, letters to the editor, and review studies from our analysis. Although, we thoroughly screened the full texts of these articles to ensure that any relevant studies that were initially overlooked, were included in our primary search. Further details of the excluded articles are defined in Fig. 1.

Fig. 1
figure 1

Flow diagram of the literature search for studies included in meta-analysis. TPE: Total Pelvic Exenteration

Full size image

Information sources and search strategy

Articles published in English were searched. To retrieved relevant articles, the search was carried out using keywords for three international databases including Medline through PubMed, Scopus and Web of Science on November 2023. Different keywords were used to search the databases, and the search strategy in PubMed is given as an example.

((((“Survival“[Mesh] OR “Mortality“[Mesh] OR “mortality” [Subheading] OR “Disease-Free Survival“[Mesh] OR “Survival Analysis“[Mesh] OR “Survival Rate“[Mesh]) OR (“Survival“[tw])) OR (“Mortality“[tw])) OR (“Disease-Free Survival“[tw])) AND (((((“Pelvic Exenteration“[Mesh]) OR (“Pelvic Exenteration“[tw])) OR (“Pelvic Exenteration“[tiab])) OR (“total Pelvic Exenteration“[tw])) OR (“total Pelvic Exenteration“[tiab]))

Data collection process

To select relevant studies, retrieved articles were entered into Endnote software and duplicate articles were removed at this stage. Then the titles and abstracts of the remaining articles were screened and irrelevant articles were discarded. After that, the full text of the remaining articles was evaluated and irrelevant articles were removed. Finally, the required information was extracted from the remaining related articles.

Data items

The required information was extracted from the full text of the retrieved articles by the authors, and in cases of disagreement, decisions were made in consultation with other authors. The data extracted from each article included the name of the first author, year of publication, type of study design, sample size, type of cancer, location of the study, MR, included sample size, quality score of studies and the study population.

Our results were divided into four groups based on type of cancer: colorectal, gynecological, urological, and miscellaneous. The miscellaneous category included data on MR of TPE regardless of cancer type. Other cancers indicated for TPE in this study included squamous cell carcinoma, soft tissue sarcoma, perineal skin cancer, anal cancer, leiomyosarcoma, etc.

MR for intra-operative mortality, in-hospital mortality, 30-and 90-day mortality, was defined as reported deaths due to the surgical procedure and MR for overall mortality included death of the patients during the follow-up period due to surgery or cancer. Notably, patients who died due to other causes or were lost to follow-up were omitted from the analysis.

Study risk of bias assessment

The Joanna Briggs Institute Critical Appraisal (JBI) checklists were used to assess the quality of the included studies [15]. For each type of article, either cohort studies or case series, we utilized the relevant checklists provided by JBI. Each item on the checklist was assigned a score of 1 if the response was “yes”, and 0 if the response was “no”, “unclear”, or “not applicable”. The quality indicators were converted to 100%, Studies addressing ≥ 75% of the checklist items were considered as having a low risk of bias [16]. One author (MSF) carried out the quality assessment.

Effect measures

Effect measures in this study was the intra-operative, in-hospital, 30-day and 90-day and overall MR following TPE. The included sample size and the number of dead people were extracted from the studies, and the MR and 95% confidence interval were calculated.

Synthesis methods and statistical analysis

To check the heterogeneity among the studies, the I2 statistic was used and it was tested using the chi-square test, and if there was significant heterogeneity between the studies, the random-effects model was used to merge the data. Although, based on the heterogeneity between the studies, from a methodological point of view, the fixed effects model was used, but considering that the mortality rate may be different based on the center expertise, surgeon experience, and postoperative care, in addition to the fixed effects model, random effects model was also performed and its results were reported. Egger’s linear regression test, Begg’s test and funnel plot were used to check publication bias. All analyzes are performed using Stata software version 16 (Stata Corp, College Station, TX).

Results

Study selection

In this systematic review, 1751 primary studies (772 papers via Medline, 936 via Scopus and 43 papers via additional search) retrieved. Of the total articles, 695 duplicate articles were identified and removed. Then, the titles and abstracts of the remaining 1153 articles were screened and at this stage, 744 articles were excluded due to the lack of fulfilling the inclusion criteria and the full text of 409 remained articles was evaluated, of which 98 articles entered into this systematic review. All the process was presented in Fig. 1.

Study characteristics

As it was shown in Tables 1 and 98 studies [6, 7, 12,13,14, 17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102] (5343 cases) were included in the analysis. The oldest one was published in 1967 and the most recent in 2023. Both case series (23 studies) and cohort studies (75 studies) were included in the analysis. The sample size of included studies ranged from 2 to 2305 cases and colorectal, gynecological, urological and miscellaneous cancers were included in the analysis. More details in this regard were presented in Table 1.

Table 1 Characteristics of Included Studies
Full size table

Risk of bias within studies

All the articles we reviewed met over 80% of the criteria in the JBI checklists and were thus included in the study. Tables 2 and 3 describe the details of evaluating the included studies according to JBI checklist for cohort studies and case series, respectively.

Table 2 Quality assessment of cohort studies according to JBI checklist
Full size table
Table 3 Quality assessment of case series according to JBI checklist
Full size table

Quantitative data synthesis and heterogeneity across studies

Colorectal cancers mortality rate

The MR following TPE in colorectal cancers was estimated and the results of meta-analysis suggested that intra-operative MR is 0.2% (n = 27, 95%CI = 0.07–1.11%, I-square = 0.0%), in-hospital MR is 3.11% (n = 31, 95%CI = 2.15–4.46%, I-square = 9.02%), 30-day MR is estimated as 2.61% (n = 35, 95%CI = 1.95–3.48%, I-square = 15.18%), 90-day MR is 6.22% (n = 12, 95%CI = 4.17–9.18%, I-square = 16.87%) and overall MR is estimated as 30.57% (n = 13, 95%CI = 26.9–34.4%, I-square = 60.6%), respectively (Table 4). All analysis was done by fixed-effects model because of no significant heterogeneity among studies. In addition, the overall MR in open surgery was 30.57%, in primary cancer 2.44%, and in primary and recurrent cancers 31.6%. There were not enough studies to perform meta-analysis for recurrent cancer.

Table 4 Summary of meta-analysis to estimate the mortality rate following TPE in colorectal cancers
Full size table

Gynecological cancers mortality rate

Regarding MR following TPE in gynecological cancers, the obtained results showed that intra-operative MR is 0.21% (n = 40, 95%CI = 0.05–0.85%, I-square = 0.0%), in-hospital MR is 2.65% (n = 34, 95%CI = 1.61–4.36%, I-square = 1.35%), 30-day MR is estimated as 5.89% (n = 37, 95%CI = 4.65–7.43%, I-square = 0.39%), 90-day MR is 2.74% (n = 7, 95%CI = 1.03–7.07%, I-square = 0.0%) and overall MR is estimated as 25.5% (n = 12, 95%CI = 19.8–32.1%, I-square = 46.6%), respectively (Table 5). All analysis was done by fixed-effects model because of no significant heterogeneity among studies. The overall MR in open surgery was 25.5%, in minimally invasive surgery was 25.0%, and in primary, recurrent and both of them together was 53.8%, 12.7% and 55.5%, respectively.

Table 5 Summary of meta-analysis to estimate the mortality rate following TPE in gynecological cancers
Full size table

Urological cancers mortality rate

In the case of urological cancers, there have been fewer studies, but still, the results showed that 30-day MR is estimated as 2.07% (n = 4, 95%CI = 1.37–3.13%, I-square = 0.0%).

Miscellaneous cancers mortality rate

The results of meta-analysis revealed that following TPE in Miscellaneous cancers, MR of intra-operative MR is 0.16% (n = 16, 95%CI = 0.02–1.1%, I-square = 56.9%), in-hospital MR is 0.8% (n = 17, 95%CI = 0.3–2.12%, I-square = 57.6%), 30-day MR is estimated as 1.59% (n = 18, 95%CI = 1.23–2.04%, I-square = 6.01%), 90-day MR is 2.33% (n = 4, 95%CI = 1.11–4.8%, I-square = 0.0%), and overall MR is estimated as 12.42% (n = 3, 95%CI = 9.2–16.6%, I-square = 39.7%) (Table 6). These rates for surgeries are reported in Table 6, but for other cases, due to the lack of sufficient studies, meta-analysis was not performed.

Table 6 Summary of meta-analysis to estimate the mortality rate following TPE in Misc. cancers
Full size table

Discussion

In this study, we investigated the MR after TPE using meta-analysis method, which included different types of cancers such as colorectal, gynecological, urological and miscellaneous cancers. The main findings of this study showed that the highest mortality rate was related to overall mortality. The overall mortality rate was 30.57% in colorectal cancers, 25.5% in gynecological cancers and 12.42% in Miscellaneous. In fact, the highest rate of mortality is related to the overall mortality rate of colorectal cancers. Naturally, the MR in open surgeries was higher than in minimally invasive surgeries, and also in primary advanced cancers, it was higher than in recurrent cancers.

Generally, TPE is used in the treatment of advanced gynecological cancers as well as primary advanced and recurrent rectal cancers, so it is mostly used in cases where conventional treatment modalities do not have a suitable prognosis. Due to the fact that the stage of cancer is higher and the prognosis is worse in patients who are candidates for this surgery, it is expected that the MR will be higher, on the other hand, this surgery is considered as an advanced surgery, and its success rate depends on the experience of the surgeon and the equipment of the surgical center.

In a study by Vigneswaran et al. [94] with the largest sample size conducted in the USA, 2305 cases of TPE between 2005 and 2016 were evaluated. Of these, 45% were urological malignancies, 33% colorectal, 15% gynecological and 9% other cancers. The authors have stated that despite the common complications in this surgery, the mortality rate is relatively low and the outcomes during and after the operation are dissimilar in different types of cancer. Also, the prevalence of major complications is 15%, 30-day mortality is 2%, the duration of hospitalization after surgery is 9 days, and blood transfusion is reported in 50% of cases. The results of the present meta-analysis estimated the 30-day mortality rate to be 2.61%, 5.89%, 1.59% and 2.07% in colorectal, gynecological, miscellaneous and urological cancer which is higher than the value reported in the aforementioned study in most cases. Part of this difference can be related to better equipment and care in USA medical centers and part of it to more experience of medical centers and surgical teams. In our study, the results showed that the overall mortality rate in gynecological malignancies is lower than that in colorectal cancers (25.5% vs. 30.57%). Although in the study of Vigneswaran et al. [94], no significant difference was reported in the 30-day mortality rate of different cancers, but the prevalence of complications was higher in gynecological cancers, and the return to the operating room due to complications was also higher in gynecological cancers than in colorectal cancer (12.8% vs. 8.7%), while it was 4.8% for urological cancers.

Intra-operative mortality rate in colorectal cancers with rate of 0.21% showed the highest rate among studied cancers and its value in all other cancers were 0.2% or less. In terms of in-hospital mortality, this rate was estimated at 3.11% for colorectal cancer, and the highest rate of in-hospital mortality rate was related to colorectal cancer. Therefore, the results of our study showed that in performing TPE for colorectal cancers, intraoperative, in-hospital, 30-day, 90-day and overall mortality rate is more than gynecological, urological, and miscellaneous cancers.

It is important to note that while recent advancements in surgical techniques and well-equipped surgical centers have improved mortality rates for TPE, the main rationale for such an aggressive surgery is the potential chance for a cure, which has been reported in up to 63% of patients [103]. However, the effectiveness of alternative options such as robotic-assisted or laparoscopic surgeries in achieving this goal has not been thoroughly studied [104]. One notable study by Bizzarri et al. [83] reported a 30-day mortality rate of 0% following minimally invasive TPE, demonstrating its feasibility in a small group of 5 patients. More research is needed to fully understand the outcomes of minimally invasive TPE compared to conventional surgical method.

The complexity of the TPE procedure makes it challenging to predict outcomes. Factors such as the purpose of surgery (curative or palliative), cancer type, patient comorbidities, and the expertise of the surgical team and center are known to be associated with morbidity and mortality [94, 104, 105]. Patients undergoing TPE also require strong physical and emotional support. Therefore, a skilled multi-disciplinary team is essential for evaluating patient eligibility and performing the surgery. Previous studies have emphasized the use of specific guidelines, such as the enhanced recovery after surgery (ERAS) guideline, to reduce complications [94, 106]. Ultimately, individualized patient selection is recommended before performing TPE.

To the best of our knowledge, this is the largest meta-analysis of MR following TPE. However, several limitations should be acknowledged. Our data may be biased towards reporting more studies with a 0% MR. This is mainly because if a study reported a 0% MR for a specific time period, the MR for previous periods would be assumed to be 0% as well, even if it wasn’t reported in detail. However, if a study reported a MR higher than 0% for a specific time period and didn’t report the previous MRs, those data points were labeled as missing. Furthermore, in this study we included as much studies as possible, to create a holistic picture of MR following TPE. Therefore, it might be subject to bias as all TPE performed since 1976 with proper definition of TPE were included in our analysis. Further studies are required to investigate the impact of surgical intention, surgical center expertise, post-operation care, and patients’ comorbidities on MR following TPE.

Conclusion

In conclusion, it can be said that performing TPE in a specialized surgical center with careful patient eligibility evaluation is a viable option for advanced malignancies of the pelvic organs.

Data availability

All data generated or analyzed during this study are included in the article.

References

  1. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. A one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;1(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  2. Pleth Nielsen CK, Sørensen MM, Christensen HK, Funder JA. Complications and survival after total pelvic exenteration. Eur J Surg Oncol. 2022;48(6):1362–7.

    Article  PubMed  Google Scholar 

  3. Miri SR, Akhavan S, Mousavi AS, Hashemi SR, Sheikhhasan S, Almasi-Hashiani A, Sadegh Fakhari M, Esmailzadeh A. A systematic review on overall survival and disease-free survival following total pelvic exenteration. Asian Pac J cancer Prevention: APJCP. 2022;23(4):1137–45.

    Article  Google Scholar 

  4. Straubhar AM, Chi AJ, Zhou QC, Iasonos A, Filippova OT, Leitao MM Jr., Awowole IO, Abu-Rustum NR, Broach VA, Jewell EL, et al. Pelvic exenteration for recurrent or persistent gynecologic malignancies: clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecol Oncol. 2021;163(2):294–8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Shaikh I, Nasir I, Gani A, Mureb A, Dowsett D, Haywood R, Rosich Medina A, Al Kadhi O, Parvaiz A, Kapur S. Robotic total pelvic exenteration – a video vignette. Colorectal Dis. 2021;23(7):1946–1946.

    Article  PubMed  Google Scholar 

  6. Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. 2005;99(1):153–9.

    Article  PubMed  Google Scholar 

  7. Goldberg GL, Sukumvanich P, Einstein MH, Smith HO, Anderson PS, Fields AL. Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol. 2006;101(2):261–8.

    Article  PubMed  Google Scholar 

  8. Lambrou NC, Pearson JM, Averette HE. Pelvic exenteration of gynecologic malignancy: indications, and technical and reconstructive considerations. Surg Oncol Clin N Am. 2005;14(2):289–300.

    Article  PubMed  Google Scholar 

  9. Lakhman Y, Nougaret S, Miccò M, Scelzo C, Vargas HA, Sosa RE, Sutton EJ, Chi DS, Hricak H, Sala E. Role of MR Imaging and FDG PET/CT in selection and follow-up of patients treated with pelvic exenteration for gynecologic malignancies. Radiographics: Rev Publication Radiological Soc North Am Inc. 2015;35(4):1295–313.

    Article  Google Scholar 

  10. Terán-Porcayo MA, Zeichner-Gancz I, del-Castillo RA, Beltrán-Ortega A, Solorza-Luna G. Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico. Med Oncol (Northwood Lond Engl). 2006;23(2):219–23.

    Article  Google Scholar 

  11. Luna-Perez P, Rodriguez DF, Flores D, Delgado S, Labastida S. Morbidity and mortality following preoperative radiation therapy and total pelvic exenteration for primary rectal adenocarcinoma. Surg Oncol. 1995;4(6):295–301.

    Article  CAS  PubMed  Google Scholar 

  12. Russo P, Ravindran B, Katz J, Paty P, Guillem J, Cohen AM. Urinary diversion after total pelvic exenteration for rectal cancer. Ann Surg Oncol. 1999;6(8):732–8.

    Article  CAS  PubMed  Google Scholar 

  13. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau D, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol. 2003;170(5):1868–71.

    Article  PubMed  Google Scholar 

  14. Katory M, McLean R, Paez E, Kucukmetin A, Naik R. Short- and long-term outcomes following pelvic exenteration for gynae-oncological and colorectal cancers: a 9 year consecutive single-centre cohort study. Int J Surg (London England). 2017;43:38–45.

    Article  Google Scholar 

  15. Institute JB, The Joanna Briggs Institute Levels of Evidence and Grades of Recommendation Working Party*. Supporting Document for the Joanna Briggs Institute Levels of Evidence and Grades of Recommendation Austrália: Joanna Briggs Institute 2014:2019 – 2005.

  16. Peters MD, Godfrey CM, McInerney P, Soares CB, Khalil H, Parker D. The Joanna Briggs Institute reviewers’ manual 2015: methodology for JBI scoping reviews. 2015.

  17. Ingiulla W, Cosmi EV. Pelvic exenteration for advanced carcinoma of the cervix. Some reflections on 241 cases. Am J Obstet Gynecol. 1967;99(8):1083–6.

    Article  CAS  PubMed  Google Scholar 

  18. Thornton WN Jr, Flanagan WC Jr. Pelvic exenteration in the treatment of advanced malignancy of the vulva. Am J Obstet Gynecol. 1973;117(6):774–81.

    Article  PubMed  Google Scholar 

  19. Karlen JR, Piver MS. Reduction of mortality and morbidity associated with pelvic exenteration. Gynecol Oncol. 1975;3(2):164–7.

    Article  CAS  PubMed  Google Scholar 

  20. Eckhauser FE, Lindenauer SM, Morley GW. Pelvic exenteration for advanced rectal carcinoma. Am J Surg. 1979;138(3):412–4.

    Article  CAS  PubMed  Google Scholar 

  21. Ledesma EJ, Bruno S, Mittelman A. Total pelvic exenteration in colorectal disease: a 20-year experience. Ann Surg. 1981;194(6):701–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Mori T, Tominaga T, Itoh I. Results of pelvic exenteration. World J Surg. 1981;5(5):749–50.

    Article  CAS  PubMed  Google Scholar 

  23. Boey J, Wong J, Ong GB. Pelvic exenteration for locally advanced colorectal carcinoma. Ann Surg. 1982;195(4):513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Takagi H, Morimoto T, Yasue M, Kato K, Yamada E, Suzuki R. Total pelvic exenteration for advanced carcinoma of the lower colon. J Surg Oncol. 1985;28(1):59–62.

    Article  CAS  PubMed  Google Scholar 

  25. Cuevas HR, Torres A, Garza MDL, Hernandez D, Herrera L. Pelvic exenteration for carcinoma of the cervix: analysis of 252 cases. J Surg Oncol. 1988;38(2):121–5.

    Article  Google Scholar 

  26. Yeung RS, Moffat FL, Falk RE. Pelvic exenteration for recurrent and extensive primary colorectal adenocarcinoma. Cancer. 1993;72(6):1853–8.

    Article  CAS  PubMed  Google Scholar 

  27. Liu SY, Wang YN, Zhu WQ, Gu WL, Fu H. Total pelvic exenteration for locally advanced rectal carcinoma. Dis Colon Rectum. 1994;37(2):172–4.

    Article  CAS  PubMed  Google Scholar 

  28. Lopez MJ, Standiford SB, Skibba JL. Total pelvic exenteration. A 50-year experience at the Ellis Fischel Cancer Center. Archives of surgery (Chicago, Ill: 1960) 1994, 129(4):390–395; discussion 395–396.

  29. Sardi A, Bolton JS, Hicks TC, Skenderis BS. 2nd: total pelvic exenteration with or without sacral resection in patients with recurrent colorectal cancer. South Med J. 1994;87(3):363–9.

    Article  CAS  PubMed  Google Scholar 

  30. Woodhouse CR, Plail RO, Schlesinger PE, Shepherd JE, Hendry WF, Breach NM. Exenteration as palliation for patients with advanced pelvic malignancy. Br J Urol. 1995;76(3):315–20.

    Article  CAS  PubMed  Google Scholar 

  31. Luna-Perez P. Patterns of recurrence following pelvic exenteration and external radiotherapy for locally advanced primary rectal adenocarcinoma. Ann Surg Oncol. 1996;3(6):526–33.

    Article  CAS  PubMed  Google Scholar 

  32. Shirouzu K, Isomoto H, Kakegawa T. Total pelvic exenteration for locally advanced colorectal carcinoma. Br J Surg. 1996;83(1):32–5.

    Article  CAS  PubMed  Google Scholar 

  33. Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg. 2000;190(1):78–83.

    Article  CAS  PubMed  Google Scholar 

  34. Chen HS, Sheen-Chen SM. Total pelvic exenteration for primary local advanced colorectal cancer. World J Surg. 2001;25(12):1546–9.

    Article  CAS  PubMed  Google Scholar 

  35. Wiig JN, Poulsen JP, Larsen S, Brændengen M, Waehre H, Giercksky KE. Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer. Eur J Surg. 2002;168(1):42–8.

    Article  PubMed  Google Scholar 

  36. Ike H, Shimada H, Yamaguchi S, Ichikawa Y, Fujii S, Ohki S. Outcome of total pelvic exenteration for primary rectal cancer. Dis Colon Rectum. 2003;46(4):474–80.

    Article  PubMed  Google Scholar 

  37. Jimenez RE, Shoup M, Cohen AM, Paty PB, Guillem J, Wong WD. Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer. Dis Colon Rectum. 2003;46(12):1619–25.

    Article  PubMed  Google Scholar 

  38. Kakuda JT, Lamont JP, Chu DZ, Paz IB. The role of pelvic exenteration in the management of recurrent rectal cancer. Am J Surg. 2003;186(6):660–4.

    Article  PubMed  Google Scholar 

  39. Vitelli CE, Crenca F, Fortunato L, Di Nardo A, Farina M, Mustacciuoli G. Pelvic exenterative procedures for locally advanced or recurrent colorectal carcinoma in a community hospital. Tech Coloproctol. 2003;7(3):159–63.

    Article  CAS  PubMed  Google Scholar 

  40. Houvenaeghel G, Moutardier V, Karsenty G, Bladou F, Lelong B, Buttarelli M, Delpero JR. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients. Gynecol Oncol. 2004;92(2):680–3.

    Article  CAS  PubMed  Google Scholar 

  41. Moriya Y, Akasu T, Fujita S, Yamamoto S. Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum. 2004;47(12):2047–53. discussion 2053 – 2044.

    Article  PubMed  Google Scholar 

  42. Leibovici D, Pagliaro L, Rosser CJ, Pisters LL. Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol. 2005;173(3):781–3.

    Article  PubMed  Google Scholar 

  43. Nguyen DQ, McGregor AD, Freites O, Carr ND, Beynon J, El-Sharkawi AM, Lucas MG. Exenterative pelvic surgery–eleven year experience of the Swansea Pelvic Oncology Group. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2005;31(10):1180–4.

    Article  CAS  Google Scholar 

  44. de Wilt JH, van Leeuwen DH, Logmans A, Verhoef C, Kirkels WJ, Vermaas M, Ansink AC. Pelvic exenteration for primary and recurrent gynaecological malignancies. Eur J Obstet Gynecol Reprod Biol. 2007;134(2):243–8.

    Article  PubMed  Google Scholar 

  45. Park JY, Choi HJ, Jeong SY, Chung J, Park JK, Park SY. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: analysis of risk factors predicting recurrence and survival. J Surg Oncol. 2007;96(7):560–8.

    Article  PubMed  Google Scholar 

  46. Vermaas M, Ferenschild FT, Verhoef C, Nuyttens JJ, Marinelli AW, Wiggers T, Kirkels WJ, Eggermont AM, de Wilt JH. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2007;33(4):452–8.

    Article  CAS  Google Scholar 

  47. Wells BJ, Stotland P, Ko MA, Al-Sukhni W, Wunder J, Ferguson P, Lipa J, Last L, Smith AJ, Swallow CJ. Results of an aggressive approach to resection of locally recurrent rectal cancer. Ann Surg Oncol. 2007;14(2):390–5.

    Article  PubMed  Google Scholar 

  48. Ungar L, Palfalvi L, Novak Z. Primary pelvic exenteration in cervical cancer patients. Gynecol Oncol. 2008;111(2 Suppl):S9–12.

    Article  PubMed  Google Scholar 

  49. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH. Total pelvic exenteration for primary and recurrent malignancies. World J Surg. 2009;33(7):1502–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Maggioni A, Roviglione G, Landoni F, Zanagnolo V, Peiretti M, Colombo N, Bocciolone L, Biffi R, Minig L, Morrow CP. Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. Gynecol Oncol. 2009;114(1):64–8.

    Article  PubMed  Google Scholar 

  51. Puntambekar S, Agarwal G, Puntambekar S, Sathe R, Patil A. Stretching the limits of laparoscopy in gynecological oncology: technical feasibility of doing a laparoscopic total pelvic exenteration for palliation in advanced cervical cancer. Int J Biomedical Science: IJBS. 2009;5(1):17.

    Article  CAS  Google Scholar 

  52. Spahn M, Weiss C, Bader P, Frohneberg D, Studer UE, Burkhard FC. The role of exenterative surgery and urinary diversion in persistent or locally recurrent gynecological malignancy: complications and survival. Urol Int. 2010;85(1):16–22.

    Article  CAS  PubMed  Google Scholar 

  53. Zoucas E, Frederiksen S, Lydrup ML, Månsson W, Gustafson P, Alberius P. Pelvic exenteration for advanced and recurrent malignancy. World J Surg. 2010;34(9):2177–84.

    Article  PubMed  Google Scholar 

  54. Chokshi RJ, Fowler J, Cohn D, Bahnson R, Lumbley J, Martin EW Jr. A single-institution approach to total pelvic exenteration. Am Surg. 2011;77(12):1629–39.

    Article  PubMed  Google Scholar 

  55. Domes TS, Colquhoun PH, Taylor B, Izawa JI, House AA, Luke PP, Izawa JI. Total pelvic exenteration for rectal cancer: outcomes and prognostic factors. Can J Surg J canadien de chirurgie. 2011;54(6):387–93.

    Article  Google Scholar 

  56. Guimarães GC, Baiocchi G, Ferreira FO, Kumagai LY, Fallopa CC, Aguiar S, Rossi BM, Soares FA, Lopes A. Palliative pelvic exenteration for patients with gynecological malignancies. Arch Gynecol Obstet. 2011;283(5):1107–12.

    Article  PubMed  Google Scholar 

  57. Mitulescu G, Gluck G, Stîngu C. Radical surgical treatement in pelvic advanced cancer. Annals Fundeni Hosp. 2011;16(3–4):87–106.

    Google Scholar 

  58. Baiocchi G, Guimaraes GC, Rosa Oliveira RA, Kumagai LY, Faloppa CC, Aguiar S, Begnami MD, Soares FA, Lopes A. Prognostic factors in pelvic exenteration for gynecological malignancies. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2012;38(10):948–54.

    Article  CAS  Google Scholar 

  59. Kuhrt MP, Chokshi RJ, Arrese D, Martin EW Jr. Retrospective review of pelvic malignancies undergoing total pelvic exenteration. World J Surg Oncol. 2012;10:110.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Ramamurthy R, Duraipandian A. Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies. Indian J Surg Oncol. 2012;3(3):231–5.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Yoo HJ, Lim MC, Seo SS, Kang S, Yoo CW, Kim JY, Park SY. Pelvic exenteration for recurrent cervical cancer: ten-year experience at national cancer center in Korea. J Gynecologic Oncol. 2012;23(4):242–50.

    Article  Google Scholar 

  62. Jäger L, Nilsson PJ, Rådestad AF. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2013;23(4):755–62.

    Article  Google Scholar 

  63. Tan KK, Pal S, Lee PJ, Rodwell L, Solomon MJ. Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca–a single institution’s experience over 16 years. Colorectal Disease: Official J Association Coloproctology Great Br Irel. 2013;15(10):1227–31.

    Article  CAS  Google Scholar 

  64. Ueda T, Koyama F, Nakagawa T, Nakamura S, Nishigori N, Inoue T, Kawasaki K, Obara S, Nakamoto T, Fujii H, et al. Clinical outcomes of pelvic exenteration for locally advanced primary or recurrent non-colorectal pelvic malignancies. Gan Kagaku Ryoho Cancer Chemother. 2013;40(12):2433–6.

    Google Scholar 

  65. Milne T, Solomon MJ, Lee P, Young JM, Stalley P, Harrison JD, Austin KK. Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies. Dis Colon Rectum. 2014;57(10):1153–61.

    Article  PubMed  Google Scholar 

  66. Pathiraja P, Sandhu H, Instone M, Haldar K, Kehoe S. Should pelvic exenteration for symptomatic relief in gynaecology malignancies be offered? Arch Gynecol Obstet. 2014;289:657–62.

    Article  CAS  PubMed  Google Scholar 

  67. Petruzziello A, Kondo W, Hatschback SB, Guerreiro JA, Filho FP, Vendrame C, Luz M, Ribeiro R. Surgical results of pelvic exenteration in the treatment of gynecologic cancer. World J Surg Oncol. 2014;12:279.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Tanaka S, Nagase S, Kaiho-Sakuma M, Nagai T, Kurosawa H, Toyoshima M, Tokunaga H, Otsuki T, Utsunomiya H, Takano T, et al. Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer. Int J Clin Oncol. 2014;19(1):133–8.

    Article  PubMed  Google Scholar 

  69. Xin KY, Ng DW, Tan GH, Teo MC. Role of pelvic exenteration in the management of locally advanced primary and recurrent rectal cancer. J Gastrointest cancer. 2014;45(3):291–7.

    Article  PubMed  Google Scholar 

  70. Cəpîlna ME, Moldovan B, Szabo B. Pelvic exenteration - our initial experience in 15 cases. Eur J Gynaecol Oncol. 2015;36(2):142–5.

    PubMed  Google Scholar 

  71. Ghouti L, Pereira P, Filleron T, Humeau M, Guimbaud R, Selves J, Carrere N. Pelvic exenterations for specific extraluminal recurrences in the era of total mesorectal excision: is there still a chance for cure? A single-center review of patients with extraluminal pelvic recurrence for rectal cancer from March 2004 to November 2010. Am J Surg. 2015;209(2):352–62.

    Article  PubMed  Google Scholar 

  72. Kusters M, Austin KK, Solomon MJ, Lee PJ, Nieuwenhuijzen GA, Rutten HJ. Survival after pelvic exenteration for T4 rectal cancer. Br J Surg. 2015;102(1):125–31.

    Article  CAS  PubMed  Google Scholar 

  73. Moreno-Palacios E, Diestro MD, De Santiago J, Hernández A, Zapardiel I. Pelvic exenteration in Gynecologic Cancer: La Paz University Hospital Experience. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2015;25(6):1109–14.

    Article  Google Scholar 

  74. Rombouts AJ, Koh CE, Young JM, Masya L, Roberts R, De-Loyde K, de Wilt JH, Solomon MJ. Does radiotherapy of the primary rectal cancer affect prognosis after pelvic exenteration for recurrent rectal cancer? Dis Colon Rectum. 2015;58(1):65–73.

    Article  PubMed  Google Scholar 

  75. Koda K, Shuto K, Matsuo K, Kosugi C, Mori M, Hirano A, Hiroshima Y, Tanaka K. Layer-oriented total pelvic exenteration for locally advanced primary colorectal cancer. Int J Colorectal Dis. 2016;31(1):59–66.

    Article  PubMed  Google Scholar 

  76. Schmidt AM, Imesch P, Fink D, Egger H. Pelvic exenterations for Advanced and recurrent endometrial Cancer: clinical outcomes of 40 patients. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2016;26(4):716–21.

    Article  Google Scholar 

  77. Chew MH, Yeh YT, Toh EL, Sumarli SA, Chew GK, Lee LS, Tan MH, Hennedige TP, Ng SY, Lee SK, et al. Critical evaluation of contemporary management in a new pelvic exenteration unit: the first 25 consecutive cases. World J Gastrointest Oncol. 2017;9(5):218–27.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Aslim EJ, Chew MH, Chew GK, Lee LS. Urological outcomes following pelvic exenteration for advanced pelvic cancer are not inferior to those following radical cystectomy. ANZ J Surg. 2018;88(9):896–900.

    Article  PubMed  Google Scholar 

  79. Hagemans JAW, Rothbarth J, Kirkels WJ, Boormans JL, van Meerten E, Nuyttens J, Madsen EVE, Verhoef C, Burger JWA. Total pelvic exenteration for locally advanced and locally recurrent rectal cancer in the elderly. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2018;44(10):1548–54.

    Article  CAS  Google Scholar 

  80. Li L, Ma SQ, Tan XJ, Zhong S, Wu M. Pelvic exenteration for recurrent and persistent cervical Cancer. Chin Med J. 2018;131(13):1541–8.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Mehta AM, Hellawell G, Burling D, Littler S, Antoniou A, Jenkins JT. Transperineal retropubic approach in total pelvic exenteration for advanced and recurrent colorectal and anal cancer involving the penile base: technique and outcomes. Tech Coloproctol. 2018;22(9):663–71.

    Article  CAS  PubMed  Google Scholar 

  82. Romeo A, Gonzalez MI, Jaunarena J, Zubieta ME, Favre G, Tejerizo JC. Pelvic exenteration for gynecologic malignancies: postoperative complications and oncologic outcomes. Actas Urol Esp. 2018;42(2):121–5.

    Article  CAS  PubMed  Google Scholar 

  83. Bizzarri N, Chiantera V, Ercoli A, Fagotti A, Tortorella L, Conte C, Cappuccio S, Di Donna MC, Gallotta V, Scambia G, et al. Minimally invasive pelvic exenteration for gynecologic malignancies: a multi-institutional Case Series and Review of the literature. J Minim Invasive Gynecol. 2019;26(7):1316–26.

    Article  PubMed  Google Scholar 

  84. de Gregorio N, de Gregorio A, Ebner F, Friedl TWP, Huober J, Hefty R, Wittau M, Janni W, Widschwendter P. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet. 2019;300(1):161–8.

    Article  PubMed  Google Scholar 

  85. Kiiski J, Räikkönen K, Vuento MH, Hyöty MK, Kallio J, Kuokkanen HO, Kaartinen IS. Transverse myocutaneous Gracilis flap reconstruction is feasible after pelvic exenteration: 12-year surgical and oncological results. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2019;45(9):1632–7.

    Article  Google Scholar 

  86. Lago V, Poveda I, Padilla-Iserte P, Simón-Sanz E, García-Granero Á, Pontones JL, Matute L, Domingo S. Pelvic exenteration in gynecologic cancer: complications and oncological outcome. Gynecol Surg 2019, 16(1).

  87. Lee P, Tan WJ, Brown KGM, Solomon MJ. Addressing the empty pelvic syndrome following total pelvic exenteration: does mesh reconstruction help? Colorectal Disease: Official J Association Coloproctology Great Br Irel. 2019;21(3):365–9.

    Article  CAS  Google Scholar 

  88. Nedyalkov K, Magunska N, Bechev B, Kostov I. Survival rate and complications after different types of pelvic exenteration for gynecological cancer. Eur J Gynaecol Oncol. 2019;40(1):69–73.

    Google Scholar 

  89. Rema P, Suchetha S, Mathew AP, George P, Mathew A, Thomas S. Pelvic exenterations for Cervical Cancer Recurrences—a safe option in Indian scenario. Indian J Surg. 2019;81(6):537–42.

    Article  Google Scholar 

  90. Soeda S, Furukawa S, Sato T, Ueda M, Kamo N, Endo Y, Kojima M, Nomura S, Kataoka M, Fujita S, et al. Pelvic exenteration as potential cure and Symptom Relief in Advanced and recurrent Gynaecological Cancer. Anticancer Res. 2019;39(10):5631–7.

    Article  PubMed  Google Scholar 

  91. Tortorella L, Casarin J, Mara KC, Weaver AL, Multinu F, Glaser GE, Cliby WA, Scambia G, Mariani A, Kumar A. Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies. Gynecol Oncol. 2019;152(1):151–6.

    Article  CAS  PubMed  Google Scholar 

  92. Lewandowska A, Szubert S, Koper K, Koper A, Cwynar G, Wicherek L. Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer. World J Surg Oncol 2020, 18(1).

  93. Tuech JJ, Pinson J, Nouhaud FX, Wood G, Clavier T, Sabourin JC, Di Fiore F, Monge M, Papet E, Coget J. Total pelvic exenteration, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy for rectal cancer with associate peritoneal metastases: Surgical strategies to optimize safety. Cancers. 2020;12(11):1–14.

    Article  Google Scholar 

  94. Vigneswaran HT, Schwarzman LS, Madueke IC, David SML, Nordenstam J, Moreira D, Abern MR. Morbidity and Mortality of Total Pelvic Exenteration for Malignancy in the US. Annals of surgical oncology 2020.

  95. Bogner A, Fritzmann J, Müssle B, Huber J, Dobroschke J, Bork U, Wolk S, Distler M, Weitz J, Welsch T et al. Pelvic exenteration for colorectal and non-colorectal cancer: a comparison of perioperative and oncological outcome. Int J Colorectal Dis 2021.

  96. Brown KGM, Ansari N, Solomon MJ, Austin KKS, Hamilton AER, Young CJ. Pelvic exenteration combined with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced primary or recurrent colorectal cancer with peritoneal metastases. Colorectal Dis. 2021;23(1):186–91.

    Article  CAS  PubMed  Google Scholar 

  97. Kanao H, Aoki Y, Omi M, Nomura H, Tanigawa T, Okamoto S, Chang EJ, Kurita T, Netsu S, Matoda M et al. Laparoscopic pelvic exenteration and laterally extended endopelvic resection for postradiation recurrent cervical carcinoma: Technical feasibility and short-term oncologic outcome. Gynecologic oncology 2021.

  98. Ter Glane L, Hegele A, Wagner U, Boekhoff J. Pelvic exenteration for recurrent or advanced gynecologic malignancies–analysis of outcome and complications. Gynecologic Oncol Rep. 2021;36:100757.

    Article  CAS  Google Scholar 

  99. Abdulrahman GO, Das N, Chandrasekaran TV, Khot U, Drew PJ, Bose P, Vet JN, Tofazzal N, Roberts S, Lutchman Singh K. Pelvic exenteration for the treatment of locally advanced vulvar cancer in south west wales. Cancers. 2022;14(7):1767.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Bouraoui I, Bouaziz H, Tounsi N, Ben Romdhane R, Hechiche M, Slimane M, Rahal K. Survival after pelvic exenteration for cervical cancer. J Obstet Gynecol India. 2022;72(1):66–71.

    Article  Google Scholar 

  101. Haidopoulos D, Pergialiotis V, Aggelou K, Thomakos N, Alexakis N, Stamatakis E, Rodolakis A. Pelvic exenteration for gynecologic malignancies: the experience of a tertiary center from Greece. Surg Oncol. 2022;40:101702.

    Article  PubMed  Google Scholar 

  102. Nielsen CKP, Sørensen MM, Christensen HK, Funder JA. Complications and survival after total pelvic exenteration. Eur J Surg Oncol. 2022;48(6):1362–7.

    Article  Google Scholar 

  103. Brown KG, Solomon MJ, Koh CE. Pelvic exenteration surgery: the evolution of radical surgical techniques for advanced and recurrent pelvic malignancy. Dis Colon Rectum. 2017;60(7):745–54.

    Article  PubMed  Google Scholar 

  104. Diver EJ, Rauh-Hain JA, Del Carmen MG. Total pelvic exenteration for gynecologic malignancies. International Journal of Surgical Oncology 2012, 2012.

  105. Kroon HM, Dudi-Venkata N, Bedrikovetski S, Thomas M, Kelly M, Aalbers A, Aziz NA, Abraham-Nordling M, Akiyoshi T, Alberda W. Palliative pelvic exenteration: a systematic review of patient-centered outcomes. Eur J Surg Oncol. 2019;45(10):1787–95.

    Article  Google Scholar 

  106. Nelson G, Bakkum-Gamez J, Kalogera E, Glaser G, Altman A, Meyer LA, Taylor JS, Iniesta M, Lasala J, Mena G. Guidelines for perioperative care in gynecologic/oncology: enhanced recovery after surgery (ERAS) society recommendations—2019 update. Int J Gynecologic Cancer 2019, 29(4).

  107. Ferron G, Querleu D, Martel P, Letourneur B, Soulié M. Laparoscopy-assisted vaginal pelvic exenteration. Gynecol Oncol. 2006;100(3):551–5.

    Article  PubMed  Google Scholar 

  108. Ogura A, Akiyoshi T, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M. Safety of laparoscopic pelvic exenteration with urinary diversion for colorectal malignancies. World J Surg. 2016;40:1236–43.

    Article  PubMed  Google Scholar 

  109. Yang K, Cai L, Yao L, Zhang Z, Zhang C, Wang X, Tang J, Li X, He Z, Zhou L. Laparoscopic total pelvic exenteration for pelvic malignancies: the technique and short-time outcome of 11 cases. World J Surg Oncol. 2015;13(1):1–9.

    Article  Google Scholar 

  110. Pokharkar A, Kammar P, D’Souza A, Bhamre R, Sugoor P, Saklani A. Laparoscopic pelvic exenteration for locally advanced rectal Cancer, technique and short-term outcomes. J Laparoendoscopic Adv Surg Techniques. 2018;28(12):1489–94.

    Article  Google Scholar 

  111. Ichihara M, Uemura M, Ikeda M, Miyake M, Kato T, Hamakawa T, Maeda S, Hama N, Nishikawa K, Miyamoto A. Safety and feasibility of laparoscopic pelvic exenteration for locally advanced or recurrent colorectal cancer. Surg Laparosc Endosc Percutan Tech. 2019;29(5):389–92.

    Article  PubMed  Google Scholar 

  112. Nonaka T, Tominaga T, Akazawa Y, Sawai T, Nagayasu T. Feasibility of laparoscopic-assisted transanal pelvic exenteration in locally advanced rectal cancer with anterior invasion. Tech Coloproctol. 2021;25:69–74.

    Article  CAS  PubMed  Google Scholar 

  113. Rios-Doria E, Filippova OT, Straubhar AM, Chi A, Awowole I, Sandhu J, Broach V, Mueller JJ, Gardner GJ, Jewell EL. A modern-day experience with Brunschwig’s operation: outcomes associated with pelvic exenteration. Gynecol Oncol. 2022;167(2):277–82.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Karkia R, Tailor A, Ellis P, Madhuri T, Scala A, Read J, Perry M, Patil K, Blackburn A, Butler-Manuel S. Minimally invasive pelvic exenteration for gynaecological malignancy: a single-centre case series and review of the literature. Eur J Obstet Gynecol Reproductive Biology. 2022;274:56–61.

    Article  Google Scholar 

  115. Quyn AJ, Murthy S, Gould L, Said H, Tiernan J, Sagar P, Antoniou A, Jenkins I, Burns EM. Clinical and oncological outcomes of pelvic exenteration surgery for anal squamous cell carcinoma. Colorectal Dis. 2023;25(11):2131–8.

    Article  PubMed  Google Scholar 

  116. Naha U, Khurshudyan A, Vigneswaran HT, Mima M, Abern MR, Moreira DM. Perioperative outcomes in male patients undergoing cystectomy, radical colorectal procedure or total pelvic exenteration. Translational Androl Urol. 2023;12(11):1631.

    Article  Google Scholar 

  117. Ralston C, Hainsworth A, de Naurois J, Schizas A, George M. Is an uncomplicated postoperative recovery following total pelvic exenteration a more important prognostic factor than achieving R0 in the first 2 years? Colorectal Dis 2023.

  118. Saqib SU, Raza MZ, Twigg J, Altan O, Bajwa AA. Feasibility of robotic platform to perform R0 resection for locally advanced multi-visceral pelvic malignancy: an institutional experience on outcomes of robotic pelvic exenteration. Langenbeck’s Archives Surg. 2023;409(1):9.

    Article  Google Scholar 

  119. Beppu N, Ito K, Otani M, Imada A, Matsubara T, Song J, Kimura K, Kataoka K, Kuwahara R, Horio Y. Feasibility of transanal minimally invasive surgery for total pelvic exenteration for advanced primary and recurrent pelvic malignancies. Tech Coloproctol 2023:1–9.

  120. Valstad H, Eyjolfsdottir B, Wang Y, Kristensen G, Skeie-Jensen T, Lindemann K. Pelvic exenteration for vulvar cancer: postoperative morbidity and oncologic outcome–A single center retrospective analysis. Eur J Surg Oncol. 2023;49(9):106958.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Not Funded.

Author information

Author notes

  1. Arezoo Esmailzadeh and Mohammad Sadegh Fakhari contributed equally to this work.

Authors and Affiliations

  1. Department of Obstetrics & Gynecology, Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

    Arezoo Esmailzadeh

  2. Student Research Committee, Arak University of Medical Sciences, Arak, Iran

    Mohammad Sadegh Fakhari

  3. Fellowship of Perinatology, Department of Gynecologic Oncology, Tehran University of Medical Sciences, Tehran, Iran

    Nafise Saedi

  4. Fellowship of Female Pelvic Medicine and Reconstructive Surgery, Yas Women Hospital, Tehran University of Medical Sciences, Tehran, Iran

    Nasim Shokouhi

  5. Department of Epidemiology, Arak University of Medical Sciences, Arak, Iran

    Amir Almasi-Hashiani

  6. Traditional and Complementary Medicine Research Center, Arak University of Medical Sciences, Arak, Iran

    Amir Almasi-Hashiani

Authors
  1. Arezoo Esmailzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Sadegh Fakhari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nafise Saedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nasim Shokouhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amir Almasi-Hashiani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AAH, AE, MSF, NS and NS conceived the study. AAH, AE, MSF, NS and NS contributed to the title, abstract and full-text screening. Data extraction was done by MSF, AE and AAH, and AAH and MSF analyzed the data. All authors contributed equally to the initial draft of the manuscript. All authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Amir Almasi-Hashiani.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esmailzadeh, A., Fakhari, M.S., Saedi, N. et al. A systematic review and meta-analysis on mortality rate following total pelvic exenteration in cancer patients. BMC Cancer 24, 593 (2024). https://doi.org/10.1186/s12885-024-12377-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-024-12377-5

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us